| Zhang Qiuning,Tian Jinhui,Li Qianru,Liu Ruifeng,Zhang Hong,Yang Yan,Wang Xiaohu.A Meta-analysis of carbon ion radiotherapy for stage I non-small cell lung cancer[J].Chinese Journal of Radiological Medicine and Protection,2016,36(8):594-600 |
| A Meta-analysis of carbon ion radiotherapy for stage I non-small cell lung cancer |
| Received:March 22, 2016 |
| DOI：10.3760/cma.j.issn.0254-5098.2016.08.008 |
| KeyWords:Carbon ion Non-small cell lung cancer Meta-analysis |
| FundProject:国家自然科学基金（81160283，81372419） |
| Author Name | Affiliation | E-mail | | Zhang Qiuning | Gansu Provincial Academic Institute for Medical Research, Gansu Provincial Cancer Hospital, Lanzhou 730050, China | | | Tian Jinhui | Institute of Modern Physics, Chinese Academy of Science, Lanzhou 730000, China | | | Li Qianru | Second Clinical Medical College of Lanzhou University, Lanzhou 730000, China | | | Liu Ruifeng | Gansu Provincial Academic Institute for Medical Research, Gansu Provincial Cancer Hospital, Lanzhou 730050, China | | | Zhang Hong | Institute of Modern Physics, Chinese Academy of Science, Lanzhou 730000, China | | | Yang Yan | Gansu Provincial Academic Institute for Medical Research, Gansu Provincial Cancer Hospital, Lanzhou 730050, China | | | Wang Xiaohu | Gansu Provincial Academic Institute for Medical Research, Gansu Provincial Cancer Hospital, Lanzhou 730050, China | xhwanggansu@163.com |
|
| Hits: 2324 |
| Download times: 2162 |
| Abstract:: |
| Objective To assess the efficacy and safety of the carbon ion radiotherapy for stage I non-small cell lung cancer (NSCLC). Methods We searched multiple electronic bibliographic databases, including the Cochrane library, PubMed, EMBASE, China Journal Full-text Database, Chinese Biomedical Database, and the Wanfang Database to assemble the available studies of carbon ion radiotherapy for stage I non-small cell lung cancer. MetaAnalyst Beta 3.13 and STATA 12.0 software were used to combine the extracted data. Results Ten studies (seven trials) were included. The overall survival rates of 1, 3 and 5 years were 95.1%, 68.5% and 45.9%, respectively. The local control rates of 1, 3 and 5 years were 90.2%, 76.7% and 81.2%, respectively. The cause specific survival rate of 1, 3 and 5 years were 82.9%, 58.5% and 57.3%, respectively. The rate of primary recurrence and total recurrence were 45.8% and 11%, respectively. The rates of total death and death from lung cancer were 52.4% and 28.3%, respectively. There were differences observed between T1 stage and T2 stage in regards to five year overall survival rate, total recurrence, lung cancer death, and grade 1 and grade 2 skin toxicities. Conclusions Available data demonstrate that carbon ion radiotherapy, in general, is a safe and feasible treatment modality for stage I NSCLC. Although current results are promising, more evidence is required before carbon ion radiotherapy can become the international standard treatment for lung cancer patients. |
| HTML View Full Text View/Add Comment Download reader |
| Close |
|
|
|
